Sensorion Releases Preliminary Documents for May 29, 2024 Shareholders' Meeting

MONTPELLIER, France--Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology firm, invites its shareholders to the Combined General Meeting on May 29, 2024, at 2 PM CET at Hotel Square Louvois, 12 rue de Louvois, 75002, Paris, France. The prior notice containing the agenda and draft resolutions was published in the BALO on April 17, 2024, with the forthcoming convening notice scheduled for publication on May 7, 2024.

Shareholders can access the meeting documents as stipulated in articles R.22-10-23 of the French Commercial Code on the company’s website from today, the twenty-second day before the meeting. Under articles R.225-83 of the French Commercial Code, these documents are available from the time the meeting is convened. Registered shareholders can request these documents until five days before the meeting, including via email, and holders of bearer shares must present a certificate of attendance from their share accounts. Additionally, shareholders can consult these documents at the company's registered office.

For any queries related to the Annual General Meeting, shareholders can send an email to contact@sensorion-pharma.com. Notably, the conditions for participating in this meeting may change in accordance with health, regulatory, and legal requirements, and shareholders are advised to stay updated by regularly checking the General Meeting section on the company’s website.

Sensorion is a pioneering clinical-stage biotech company specializing in novel therapies to address hearing loss disorders, a significant unmet medical need globally. The company has developed a unique R&D technology platform to deepen understanding of the pathophysiology and etiology of inner ear diseases. This knowledge aids in selecting optimal targets and mechanisms of action for drug candidates.

Sensorion is advancing two gene therapy programs targeting hereditary monogenic forms of deafness, in collaboration with the Institut Pasteur. The programs include SENS-501 (OTOF-GT) for deafness due to otoferlin gene mutations, currently in Phase 1/2 clinical trials, and GJB2-GT, targeting hearing loss related to GJB2 gene mutations, addressing critical hearing loss segments in both adults and children. The company also focuses on identifying biomarkers to enhance the diagnosis of these underrepresented conditions.

The company’s portfolio includes clinical-stage small molecule programs aimed at treating and preventing hearing loss disorders. Among these, SENS-401 (Arazasetron) is in Phase 2 proof of concept studies for Cisplatin-Induced Ototoxicity (CIO), and, in partnership with Cochlear Limited, is also in a study involving patients scheduled for cochlear implantation. In January 2022, a Phase 2 study of SENS-401 was completed for Sudden Sensorineural Hearing Loss (SSNHL).

Sensorion, with its innovative approach and strategic collaborations, continues to advance its mission of addressing hearing loss disorders through cutting-edge therapeutic developments, making significant strides in a field with substantial unmet medical needs.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!